PRELID3B

Across TCGA pan-cancer cohorts, PRELID3B mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PRELID3B data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PRELID3B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PRELID3B expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC and LUAD are the cancer types where PRELID3B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	III,IV	0.918	0.509	.001	69	view →
LUAD	DFS	Median	III,IV	0.793	0.343	.012	9	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

PRELID3B–HNSC (OS)

Open the HNSC breakdown →